BioSpace News Archive

First indication of human safety and pharmacokinetic profiles for SPR206 supports advancement of program to clinical pharmacology studies planned to initiate in the second half of 2020

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration

IntelGenx Corp., a leader in pharmaceutical films, provided a commercial update on its two lead product candidates, cannabis-infused VersaFilm® and RIZAPORT®.

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it has received the approval of the Toronto Stock Exchange (the “TSX”) to renew its normal course issuer bid (the “NCIB”) for up to 8,000,000 of its common shares (the “Common Shares”), representing approximately 10% of its public float of issued and outstanding Common Shares.

ContraFect Corporation announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections under Temporary Authorizations for Use from the French National Agency for Medicines and Health Products Safety in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the closing of a private placement financing (the “Offering”) resulting in gross proceeds of approximately $6.9 million from certain accredited investors

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its fourth-quarter and full-year 2019 financial results on Friday, February 7, 2020 before the market opens.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) today announced that they submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) on December 18, 2019, for Crysvita® (burosumab) for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tumor-induced osteomalacia; TIO) that cannot be curatively resected or localized.

CNS Pharmaceuticals, Inc. announced it has entered into a licensing agreement with MD Anderson to investigate WP1244, an entirely new class of DNA-binding agents designed to cross the blood brain barrier for the potential the treatment of primary and metastatic brain cancers.

Maui Derm for Dermatologies 2020 Meeting is being held from January 25-29, 2020, in Maui Hawaii